See more : AIB Group plc (AIBG.L) Income Statement Analysis – Financial Results
Complete financial analysis of Intelligent Bio Solutions Inc. (INBS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Intelligent Bio Solutions Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- GV Films Limited (GVFILM.BO) Income Statement Analysis – Financial Results
- Nighthawk Gold Corp. (NHK.TO) Income Statement Analysis – Financial Results
- SamYoung Chemical Co.,Ltd (003720.KS) Income Statement Analysis – Financial Results
- Pasco Corporation (PCRRF) Income Statement Analysis – Financial Results
- KFM Kingdom Holdings Limited (3816.HK) Income Statement Analysis – Financial Results
Intelligent Bio Solutions Inc. (INBS)
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3.11M | 1.26M | 0.00 | 1.98M | 188.74K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.69M | 930.20K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.43M | 326.67K | 0.00 | 1.98M | 188.74K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 45.81% | 25.99% | 0.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.67M | 507.42K | 3.85M | 4.27M | 588.21K | 3.18M | 2.53M | 0.00 |
| General & Administrative | 0.00 | 0.00 | 4.92M | 3.71M | 2.43M | 3.55M | 2.08M | 139.10K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 33.90K |
| SG&A | 9.26M | 8.03M | 4.92M | 3.71M | 2.43M | 3.55M | 2.08M | 173.00K |
| Other Expenses | 776.50K | 0.00 | -437.15K | -947.41K | -188.74K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 11.71M | 8.76M | 8.34M | 7.03M | 2.83M | 6.73M | 4.60M | 173.00K |
| Cost & Expenses | 13.39M | 9.69M | 8.34M | 7.03M | 2.83M | 6.73M | 4.60M | 173.00K |
| Interest Income | 84.82K | 9.68K | 14.43K | 13.81K | 97.00 | 188.00 | 564.00 | 151.28K |
| Interest Expense | 167.14K | 223.53K | 7.54K | 1.09M | 457.75K | 664.84K | 453.87K | 0.00 |
| Depreciation & Amortization | 1.20M | 966.73K | 8.34M | 5.21M | 2.60M | 5.83M | 4.60M | 188.72K |
| EBITDA | -8.81M | -9.47M | 30.83K | -1.82M | -561.19K | -1.50M | -416.92K | -151.28K |
| EBITDA Ratio | -283.14% | -593.55% | 0.00% | -361.23% | -1,433.70% | 0.00% | 0.00% | 0.00% |
| Operating Income | -10.28M | -12.60M | -8.34M | -5.57M | -2.71M | -6.73M | -4.60M | -173.00K |
| Operating Income Ratio | -330.46% | -1,002.11% | 0.00% | -281.42% | -1,433.70% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 92.24K | 1.93M | 2.90K | -1.71M | -457.75K | -664.84K | -453.31K | -138.67K |
| Income Before Tax | -10.19M | -10.66M | -8.33M | -8.52M | -3.16M | -7.39M | -5.06M | -311.67K |
| Income Before Tax Ratio | -327.50% | -848.50% | 0.00% | -430.15% | -1,676.23% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 190.70K | -27.93K | 2.50M | 550.26K | -57.69K | -36.39K | -167.01K |
| Net Income | -10.16M | -10.63M | -8.31M | -7.04M | -3.16M | -7.34M | -5.02M | -340.01K |
| Net Income Ratio | -326.40% | -845.89% | 0.00% | -355.33% | -1,676.23% | 0.00% | 0.00% | 0.00% |
| EPS | -6.38 | -10.58 | -11.33 | -16.22 | -8.92 | -21.01 | -14.60 | -0.99 |
| EPS Diluted | -6.38 | -10.58 | -11.33 | -16.22 | -8.92 | -21.01 | -14.60 | -0.99 |
| Weighted Avg Shares Out | 1.59M | 1.00M | 733.26K | 433.95K | 354.60K | 349.28K | 343.75K | 343.75K |
| Weighted Avg Shares Out (Dil) | 1.59M | 1.00M | 733.26K | 433.95K | 354.60K | 349.28K | 343.75K | 343.75K |
Intelligent Bio Solutions Inc. Announces Preliminary Unaudited Fiscal Third Quarter and Nine-Month Revenue Results
Year-over-year unaudited revenue increased 80% for the fiscal third quarter and 193% for the nine months ended March 31, 2024, with highest quarterly cartridge sales since 2022 Intelligent Fingerprinting acquisition Year-over-year unaudited revenue increased 80% for the fiscal third quarter...
Intelligent Bio Solutions Subsidiary Broadens Intellectual Property Portfolio with Grant of New European Patent with Unitary Effect for Innovative Intelligent Fingerprinting DSR-Plus Cartridge Reader
NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (“INBS” or the “Company”) (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the broadening of the intellectual property portfolio of its wholly...
Intelligent Bio Solutions to Present at the LD Micro Invitational XIV Investor Conference on April 9 in NYC
NEW YORK, March 26, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("INBS" or the "Company") (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that President and CEO, Harry Simeonidis, and CFO, Spiro Sakiris, are...
Intelligent Bio Solutions Announces Closing of $10.1 Million Private Placement Priced At-the-Market Under Nasdaq Rules
NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("INBS" or the "Company") (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the closing of its previously announced private placement priced at-the-market under...
Intelligent Bio Solutions Announces $10.1 Million Private Placement Priced At-the-Market Under Nasdaq Rules
NEW YORK, March 11, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("INBS" or the "Company") (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that on March 8, 2024, it entered into securities purchase agreements with...
Intelligent Bio Solutions Inc. to Present at the Emerging Growth Conference on March 6, 2024
NEW YORK, March 01, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it will present at the Emerging Growth Conference on...
Intelligent Bio Solutions Partners with Cliantha Research to Conduct Clinical Study as Part of FDA 510(k) Pathway
NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("INBS" or the "Company") (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its partnership with Cliantha Research, a full-service Clinical Research Organization...
Intelligent Bio Solutions Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement and Confirms Compliance with Minimum Stockholders' Equity Requirement
NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("INBS" or the "Company") (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that on February 13, 2024, it received written notification from...
Why Is Intelligent Bio Solutions (INBS) Stock Down 24% Today?
Intelligent Bio Solutions (NASDAQ: INBS ) stock is falling on Monday following the release of the medical technology company's earnings report for its fiscal second quarter of 2024. The Intelligent Bio Solutions earnings release includes adjusted earnings per share of -$2.07.
Intelligent Bio Solutions Inc. Reports Fiscal Second Quarter and Six-Month Financial Results and Operational Highlights
- Year-over-year revenue increased 114% for the fiscal second quarter and 337% for the six-months ending December 31, 2023 - - Expanded into New Zealand market and increased market share in existing regions -
Source: https://incomestatements.info
Category: Stock Reports